Zimmer Biomet stock edges lower as analysts keep a hold stance

Zimmer Biomet stock (ISIN US98956P1021) is trading at around 100.70 USD as of September 2, 2026, giving the medical device group a market capitalization of about 19.0 billion USD according to recent market data. The shares are down about 1.3 percent intraday from the previous close of 102.82 USD on the New York Stock Exchange on that date, while remaining above their 52-week low of 79.12 USD reported by MarketBeat. For European investors, Zimmer Biomet stock is also tradable via secondary listings, although the primary quotation remains on the NYSE, making its USD performance the key reference point.

Analysts see limited upside

According to an overview by MarketBeat dated September 2, 2026, Zimmer Biomet has a consensus rating of hold and an average analyst price target of 104.42 USD. With the stock at 99.52 USD at the close referenced in that overview, the implied upside to the consensus target is about 4.9 percent, signaling that analysts expect only moderate gains from current levels. The same data set notes that the stock was trading at 89.94 USD at the beginning of 2026 and has since increased to 99.52 USD, a year-to-date gain of around 11.8 percent based on the quoted figures.

In a separate research note summarized by MarketBeat on September 2, 2026, Bernstein raised its price objective for Zimmer Biomet from 91.00 USD to 93.00 USD while assigning a market perform rating. That target sits below the prevailing consensus and also below the roughly 100 USD trading level, underscoring that some analysts see the shares as fairly valued after the recent year-to-date gains. For investors comparing healthcare equipment names, this mix of a hold consensus and modest upside may position Zimmer Biomet as a relatively defensive play rather than a high-growth outlier.

Price range and valuation metrics

The same MarketBeat stock overview reports that Zimmer Biomet shares traded in a 52-week range between 79.12 USD and 106.88 USD as of early September 2026. With a last price of 99.52 USD, the stock sits roughly 26 percent above the 52-week low and about 6.9 percent below the 52-week high, highlighting that it is trading in the upper half of its recent range without revisiting prior peaks. MarketBeat lists Zimmer Biomet's market capitalization at approximately 18.98 billion USD and its price-to-earnings ratio at 24.21 based on the latest available earnings, placing the stock in a mid-20s multiple bracket typical for established medical device companies.

MarketBeat also notes that Zimmer Biomet shares started 2026 at 89.94 USD and have climbed to 99.52 USD, corresponding to an increase of around 10.7 to 11.8 percent depending on the precise reference point within the dataset. Over a one-year period highlighted by another review of medical device stocks on Stake, Zimmer Biomet's share price began at 105.01 USD and ended at 99.40 USD, a decline of 5.3 percent, with a one-year range between a high of 105.73 USD and a low of 79.58 USD according to Stake market data. This contrast between the year-to-date gain and the negative one-year change shows how the stock has recovered from lower levels but has not yet surpassed earlier highs.

Dividend and shareholder base context

MarketBeat's summary of Zimmer Biomet notes that stockholders of record on September 30 in the relevant year are scheduled to receive a quarterly dividend of 0.24 USD per share, corresponding to 0.96 USD on an annualized basis and a dividend yield of about 1.0 percent at a price level near 96 to 100 USD. For income-oriented investors, this yield is modest but signals that the company combines its medical device growth profile with a regular cash return policy. The dividend also provides a partial cushion against volatility in the share price, especially when the stock trades in the middle of its 52-week band.

Institutional investors remain an important part of the shareholder base. For example, an update from the Oakmark Equity and Income Fund shows Zimmer Biomet at a 1.3 percent portfolio weight among its positions, according to the fund overview dated in early September 2026. At the same time, filings summarized by MarketBeat highlight that some asset managers have adjusted their positions, with one filing describing changes in holdings by a large quantitative investment management firm and another citing a reduction of holdings by a unit of UBS Asset Management. These shifts underscore that professional investors actively rebalance their exposure as Zimmer Biomet's valuation and earnings outlook evolve.

Product spotlight Avitus Bone and Marrow Harvester

Beyond the stock metrics, Zimmer Biomet's business remains anchored in musculoskeletal healthcare, focusing on orthopedic implants, trauma solutions and related technologies. One representative product is the Avitus Bone and Marrow Harvester, described on a company product page as a system that quickly harvests cancellous bone and bone marrow through a minimally invasive incision from access sites such as the proximal tibia, distal tibia and calcaneus. The technology uses advanced suction curettage to obtain both cancellous bone and additional non-diluted bone marrow aspirate in a few minutes, illustrating how Zimmer Biomet continues to refine tools that support surgeons in orthopedic procedures.

For hospitals and surgeons, devices like the Avitus system can translate into shorter procedure times and potentially less invasive approaches for patients, which may support adoption in trauma and reconstructive surgeries. While individual product revenues are not separately disclosed in the available sources here, Zimmer Biomet emphasizes in its company overview that its mission is to alleviate pain and improve the quality of life for people worldwide, and its portfolio of implants, instruments and biologics is central to achieving that mission. In combination with educational initiatives through the Zimmer Biomet Institute, the group aims to maintain close relationships with specialists who use its products in daily practice.

Zimmer Biomet stock and current trading level

As of intraday trading on September 2, 2026, Zimmer Biomet stock is quoted at about 100.70 USD on the NYSE, with an intraday move of plus 1.30 USD or 1.31 percent from the previous closing price of 102.82 USD according to the live quote information on Yahoo Finance. In parallel, Stake market data cites a price of 99.40 USD and a daily change of minus 0.6 percent for one of the recent trading sessions, underscoring that the stock has been oscillating around the psychologically important 100 USD mark. With a one-year range on Stake between 79.58 USD and 105.73 USD, the current level places the shares closer to their recent highs than to their lows.

For investors observing the broader medical device sector, Zimmer Biomet's combination of an approximately 19.0 billion USD market capitalization, a price-to-earnings multiple in the mid-20s and a hold consensus with limited target-price upside suggests a profile of moderate growth with valuation already reflecting much of the near-term earnings outlook. As always, the key factors to watch include the pace of adoption of its latest orthopedic and surgical technologies, the stability of procedure volumes in core markets, and any upcoming earnings releases that could shift analyst expectations and, in turn, the trajectory of Zimmer Biomet stock.

Key data on Zimmer Biomet

• Company: Zimmer Biomet Holdings, Inc.
• ISIN: US98956P1021
• Ticker: ZBH
• Trading venue: NYSE
• Price (as of September 2, 2026, 13:36): 100.70 USD
• Market capitalization: 18.98 billion USD (as of September 2, 2026)
• Sector / Industry: Healthcare / Medical Devices
• Index membership: S and P 500